Related Experiment Video
Updated: Jul 12, 2025
07:13
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
513
1-Piperidine Propionic Acid as an Allosteric Inhibitor of Protease Activated Receptor-2
Monica Chinellato1, Matteo Gasparotto2, Santina Quarta1
1Department of Medicine, University of Padova, 35121 Padova, Italy.
Pharmaceuticals (Basel, Switzerland)
|October 28, 2023
Summary
Researchers identified 1-Piperidine Propionic Acid (1-PPA) as a potential antagonist for Protease Activated Receptors (PARs). This small molecule targets an allosteric site on PAR2, inhibiting inflammatory signaling and platelet aggregation.
Area of Science:
- Biochemistry
- Pharmacology
- Molecular Biology
Background:
- Inflammatory signaling pathways are crucial in various diseases.
- Protease Activated Receptors (PARs), particularly PAR2, are key drivers of inflammation.
- Developing PAR2 antagonists is a therapeutic focus for inflammatory conditions.
Purpose of the Study:
- To identify the molecular target of 1-Piperidine Propionic Acid (1-PPA).
- To investigate the mechanism of action of 1-PPA in inflammatory processes.
- To evaluate 1-PPA as a potential therapeutic agent targeting PAR family members.
Main Methods:
- Cellular thermal shift assay (CETSA) to detect target engagement.
- In-silico methods: molecular docking and molecular dynamics simulations.
- Functional assays to assess effects on MAPK signaling and platelet aggregation.
Main Results:
- 1-PPA was found to bind to an allosteric pocket in the inactive conformation of PAR2.
- 1-PPA demonstrated antagonist effects on MAPK signaling pathways.
- 1-PPA inhibited PAR2-mediated platelet aggregation.
Conclusions:
- 1-PPA acts as an antagonist by binding to a conserved allosteric site on PAR2.
- The binding site is conserved across the PAR family, suggesting broader applicability.
- 1-PPA shows promise as a novel small molecule therapeutic targeting PARs.
Related Concept Videos
01:19Allosteric Proteins-ATCase
5.8K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.8K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
192
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
192
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.9K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.9K
01:08Allosteric Regulation
58.1K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
58.1K
01:09GPCRs Regulate Adenylyl Cylase Activity
5.6K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.6K
00:49Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K